Role for Proton Therapy in Locally Advanced Non–Small-Cell Lung Cancer?

Video

This video reviews results of a randomized trial comparing intensity modulated radiation therapy vs passively scattered proton therapy for locally advanced non–small-cell lung cancer.

In this video, Zhongxing Liao, MD, of MD Anderson Cancer Center in Houston, Texas, reviews results of a randomized trial that compared intensity modulated radiation therapy (IMRT) vs passively scattered proton therapy in patients with locally advanced non–small-cell lung cancer.

Liao gave a presentation on this topic earlier this year at the 2017 Multidisciplinary Thoracic Cancers Symposium.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
Related Content
The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

MARIPOSA OS Results Are Significant for EGFR+ NSCLC

ONCOLOGY Staff
July 2nd 2025
Article

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.

The Role of Artificial Intelligence in Enhancing Precision Medicine for NSCLC

Puneet Modgil, MD
June 24th 2025
Article

AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Treatment Options and AE Considerations in First-Line EGFR+ NSCLC

Treatment Options and AE Considerations in First-Line EGFR+ NSCLC

ONCOLOGY Staff
June 20th 2025
Article

Experts discuss shifting preferences in EGFR-mutated NSCLC treatments, highlighting new survival data from the FLAURA2 and MARIPOSA trials shared at ELCC 2025.

Tarlatamab and the ES-SCLC Treatment Landscape: Managing AEs and Educating Patients

Tarlatamab and the ES-SCLC Treatment Landscape: Managing AEs and Educating Patients

ONCOLOGY Staff
June 19th 2025
Article

Experts discuss innovative treatments for extensive-stage small cell lung cancer, highlighting tarlatamab's potential and management of adverse effects.